| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/1744666X.2017.1372194 |
| P698 | PubMed publication ID | 28837367 |
| P50 | author | Vasiliki Liakouli | Q55273178 |
| Giuliana Guggino | Q56810321 | ||
| Piero Ruscitti | Q88511212 | ||
| Onorina Berardicurti | Q95331019 | ||
| Paola Di Benedetto | Q40484648 | ||
| Roberto Giacomelli | Q42416418 | ||
| P2093 | author name string | Francesco Carubbi | |
| Giovanni Triolo | |||
| Francesco Ciccia | |||
| Paola Cipriani | |||
| P2860 | cites work | Ferritin for the clinician | Q24642942 |
| Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome | Q28239135 | ||
| Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 | ||
| Inflammation meets cancer, with NF-κB as the matchmaker | Q29620242 | ||
| IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? | Q30251741 | ||
| Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. | Q30626213 | ||
| Immunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 production | Q30989272 | ||
| Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature | Q33370577 | ||
| Life-threatening complications of adult-onset Still's disease | Q33412732 | ||
| Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients | Q33420069 | ||
| Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis | Q33429617 | ||
| Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinra | Q33817997 | ||
| Perforin gene defects in familial hemophagocytic lymphohistiocytosis. | Q33882431 | ||
| Regulation of ferritin genes and protein | Q34126332 | ||
| The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome | Q34966670 | ||
| Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. | Q35015661 | ||
| Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis | Q35041117 | ||
| Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis | Q35064189 | ||
| Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome | Q35066319 | ||
| Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. | Q35115790 | ||
| Perforin is a critical physiologic regulator of T-cell activation | Q35125914 | ||
| The role of IL-1β in the bone loss during rheumatic diseases. | Q35540844 | ||
| Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. | Q35585941 | ||
| Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature | Q35687532 | ||
| Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome | Q35847631 | ||
| Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis | Q36015036 | ||
| Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice | Q36042041 | ||
| Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers | Q36208563 | ||
| Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. | Q44318263 | ||
| Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis | Q45400777 | ||
| Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. | Q46645329 | ||
| Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome | Q47368371 | ||
| Novel NLRC4 Mutation Causes a Syndrome of Perinatal Autoinflammation With Hemophagocytic Lymphohistiocytosis, Hepatosplenomegaly, Fetal Thrombotic Vasculopathy, and Congenital Anemia and Ascites. | Q51061979 | ||
| Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome | Q51545663 | ||
| Increased serum monocyte chemoattractant protein-1, macrophage inflammatory protein-1beta, and interleukin-8 concentrations in hemophagocytic lymphohistiocytosis. | Q51952551 | ||
| Alleviating the storm: ruxolitinib in HLH. | Q53132444 | ||
| Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. | Q53916622 | ||
| Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. | Q54337698 | ||
| TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis | Q36403570 | ||
| Tuberculosis-associated haemophagocytic syndrome. | Q36514429 | ||
| A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. | Q36655896 | ||
| Infections associated with haemophagocytic syndrome. | Q37018227 | ||
| Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells | Q37240288 | ||
| The costimulatory role of TIM molecules | Q37474954 | ||
| Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. | Q37589316 | ||
| Viral infections associated with haemophagocytic syndrome. | Q37686403 | ||
| Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial | Q37735696 | ||
| Adult haemophagocytic syndrome | Q38167486 | ||
| Methotrexate: an old new drug in autoimmune disease. | Q38253237 | ||
| Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. | Q38323485 | ||
| Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab. | Q38356706 | ||
| The role and therapeutic targeting of IL-6 in rheumatoid arthritis. | Q38685086 | ||
| Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study | Q38703626 | ||
| JAK inhibition in inflammatory bowel disease | Q38761142 | ||
| Macrophage activation syndrome in the era of biologic therapy. | Q38786756 | ||
| Baricitinib for the treatment of rheumatoid arthritis | Q38840787 | ||
| Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis | Q38851433 | ||
| Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. | Q39355242 | ||
| Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. | Q39385892 | ||
| H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease. | Q39673488 | ||
| Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients | Q39748097 | ||
| Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. | Q39761819 | ||
| Application of the 2016 EULAR/ACR/PRINTO Classification Criteria for Macrophage Activation Syndrome in Patients with Adult-onset Still Disease. | Q40060914 | ||
| Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. | Q40235629 | ||
| Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus | Q40293009 | ||
| The CD68(+)/H-ferritin(+) cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for p | Q40352271 | ||
| Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis | Q40360876 | ||
| Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. | Q40484547 | ||
| Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis | Q40490433 | ||
| An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder | Q40536555 | ||
| Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases. | Q40630673 | ||
| Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab | Q41029387 | ||
| Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide | Q42197904 | ||
| Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. | Q42260141 | ||
| Plasma exchange, methylprednisolone, IV immune globulin, and now anakinra support continued PICU equipoise in management of hyperferritinemia-associated sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocyt | Q42375787 | ||
| P433 | issue | 11 | |
| P921 | main subject | activation syndrome | Q4677466 |
| macrophage activation syndrome | Q6725504 | ||
| P304 | page(s) | 1041-1047 | |
| P577 | publication date | 2017-09-01 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? | |
| P478 | volume | 13 |
| Q47727637 | H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. |
| Q94590921 | Impact of COVID-19 pandemic on SLE: beyond the risk of infection |
| Q64235820 | Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study |
| Q97653199 | Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations |
| Q96647317 | Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm |
Search more.